The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Neoadjuvant and adjuvant chemotherapy with TME in T3 rectal cancer
Yuichiro Tsukada, MD, National Cancer Center Hospital East, Kashiwa, Japan, provides an overview of a Phase II/III trial (UMIN000009510) of neoadjuvant chemotherapy followed by total mesorectal excision (TME) and adjuvant chemotherapy in patients with in very low-lying clinical (c) T3 rectal cancer (NAIR). Patients received TME followed by adjuvant chemotherapy with or without neoadjuvant chemotherapy consisting of mFOLFOX6 or CAPOX. Addition of neoadjuvant chemotherapy significantly improved relapse-free survival and anus-preserving rates. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
